[go: up one dir, main page]

AR124866A2 - COMPOSITIONS, FORMULATIONS AND PRODUCTION AND PURIFICATION OF INTERLEUKIN - Google Patents

COMPOSITIONS, FORMULATIONS AND PRODUCTION AND PURIFICATION OF INTERLEUKIN

Info

Publication number
AR124866A2
AR124866A2 ARP220100287A ARP220100287A AR124866A2 AR 124866 A2 AR124866 A2 AR 124866A2 AR P220100287 A ARP220100287 A AR P220100287A AR P220100287 A ARP220100287 A AR P220100287A AR 124866 A2 AR124866 A2 AR 124866A2
Authority
AR
Argentina
Prior art keywords
individual
methods
purification
delivery
cholix
Prior art date
Application number
ARP220100287A
Other languages
Spanish (es)
Inventor
Derek Maclean
Tahir Mahmood
Charles Olson
Weijun Feng
Raj Tandale
Liz Bhatt
Randall J Mrsny
Bittoo Kanwar
Sally Postlethwaite
Khushdeep Mangat
Marvin Garovoy
James Andrew Whitney
Kevin Yin
Amir Porat
Hyojin Kim
Sean Dalziel
John Koleng
Original Assignee
Applied Molecular Transport Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Molecular Transport Inc filed Critical Applied Molecular Transport Inc
Publication of AR124866A2 publication Critical patent/AR124866A2/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se describen en la presente proteínas de fusión cholix-IL-10 y métodos de uso de las mismas, que pueden caracterizarse por una respuesta distinta en un individuo cuando se administran. Esta respuesta distinta pueda comprender cambios en los niveles de uno o más marcadores en el individuo y/o la co-localización de IL-10 en la lamina propria del individuo. Se describen además, en algunas modalidades, formulaciones orales de las proteínas de fusión cholix-IL-10. Se describen en la presente métodos para la purificación de un constructo de suministro de IL-10, incluyendo métodos para replegamiento y enriquecimiento, que pueden dar como resultado el mantenimiento de un alto porcentaje de los constructos de suministros de IL-10 en la forma dímera biológicamente activa. Se describen en la presente formulaciones orales configuradas para la liberación sitio específica de una proteína terapéutica en el intestino delgado o el colon. En algunos casos, la proteína terapéutica está en forma de un dímero, como un constructo de liberación de IL-10 capaz de atravesar el epitelio intestinal.Described herein are cholix-IL-10 fusion proteins and methods of use thereof, which may be characterized by a distinct response in an individual when administered. This distinct response may comprise changes in the levels of one or more markers in the individual and/or co-localization of IL-10 in the individual's lamina propria. Further disclosed, in some embodiments, are oral formulations of the cholix-IL-10 fusion proteins. Described herein are methods for the purification of an IL-10 delivery construct, including methods for refolding and enrichment, which can result in the maintenance of a high percentage of the IL-10 delivery constructs in the dimeric form. biologically active. Disclosed herein are oral formulations configured for site-specific delivery of a therapeutic protein in the small intestine or colon. In some cases, the therapeutic protein is in the form of a dimer, such as an IL-10-releasing construct capable of traversing the intestinal epithelium.

ARP220100287A 2019-08-16 2022-02-14 COMPOSITIONS, FORMULATIONS AND PRODUCTION AND PURIFICATION OF INTERLEUKIN AR124866A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962887933P 2019-08-16 2019-08-16

Publications (1)

Publication Number Publication Date
AR124866A2 true AR124866A2 (en) 2023-05-10

Family

ID=80782084

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP200102328A AR119787A1 (en) 2019-08-16 2020-08-14 COMPOSITIONS, FORMULATIONS AND PRODUCTION AND PURIFICATION OF INTERLEUKIN
ARP220100287A AR124866A2 (en) 2019-08-16 2022-02-14 COMPOSITIONS, FORMULATIONS AND PRODUCTION AND PURIFICATION OF INTERLEUKIN
ARP220100589A AR125082A2 (en) 2019-08-16 2022-03-15 PHARMACEUTICAL COMPOSITIONS AND METHOD OF PRODUCING THEM

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP200102328A AR119787A1 (en) 2019-08-16 2020-08-14 COMPOSITIONS, FORMULATIONS AND PRODUCTION AND PURIFICATION OF INTERLEUKIN

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP220100589A AR125082A2 (en) 2019-08-16 2022-03-15 PHARMACEUTICAL COMPOSITIONS AND METHOD OF PRODUCING THEM

Country Status (1)

Country Link
AR (3) AR119787A1 (en)

Also Published As

Publication number Publication date
AR119787A1 (en) 2022-01-12
AR125082A2 (en) 2023-06-07

Similar Documents

Publication Publication Date Title
CL2022000376A1 (en) Compositions, formulations and production and purification of interleukins
MX2022008771A (en) Biased il2 muteins methods and compositions.
CO2021008838A2 (en) Modified amine lipids
CY1123138T1 (en) CYTOTOXIC PROTEINS CONTAINING CELL-TARGETING BINDING REGIONS AND SHIGA TOXIN A SUBUNIT REGIONS FOR SELECTIVE KILL OF SPECIFIC CELL TYPES
CL2021000678A1 (en) Formulations of glucagon-like peptide 2 (glp-2) analogs
UY39715A (en) ANTI-IL-2R AGONIST ANTIBODIES AND METHODS OF USE
CO2019000643A2 (en) Oral gastro-retentive formulations and uses thereof
PA8583101A1 (en) NEW COMPOUNDS OF ISOTIAZOL AND ISOXAZOL AS INHIBITORS OF THE TRANSFORMING GROWTH FACTOR (TGF)
ECSP11011067A (en) COMPOUNDS FOR THE TREATMENT OF DISEASES AND OPHTHALMOLOGICAL DISORDERS
AR110299A1 (en) CONJUGATES UNDERSTANDING A DUAL GLP-1 / GLUCAGON AGONIST, A CONNECTOR AND Hyaluronic Acid
AR113422A2 (en) RECONSTITUTED SURFACTIVE AGENTS HAVING IMPROVED PROPERTIES
AR076973A1 (en) IMPROVED RECONSTITUTED TENSIOACTIVE COMPOSITION CONTAINING ANALOGS OF THE TENSIOACTIVE PROTEIN B (SP-B) AND THE TENSIOACTIVE PROTEIN C (SP-C)
CY1113948T1 (en) THERAPEUTIC ACTIVE ALPHA-MSH analogues
CR20220005A (en) PROCESSES AND INTERMEDIATE FOR THE LARGE-SCALE PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-IL]-BENZAMIDE HEMISUCCINATE AND PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-IL]-BENZAMIDE
NI202000071A (en) GLUCAGON-LIKE PEPTIDE 1 (GLP-1) FUSION PEPTIDE CONJUGATES COUPLED TO CYCLIC TYROSINE TYROSINE PEPTIDE AND USES THEREOF
CO2024011162A2 (en) NLRP3 inhibitors
EA202191280A1 (en) DELIVERY CONSTRUCTS FOR TRANSCYTOSIS AND RELATED METHODS
BR112022016744A2 (en) METHODS TO REDUCE POLYSORBATE DEGRADATION IN DRUG FORMULATIONS
CO2021013677A2 (en) Process for the manufacture of stable bacterial extracts and their use as drugs
CO2023008676A2 (en) Lactam modified polypeptide compounds
AR128627A1 (en) THERAPEUTIC AGENT FOR NEURODEGENERATIVE DISEASES
CO2022011183A2 (en) Antiviral protein-compound conjugates
PE20210779A1 (en) NEW STABLE HIGH CONCENTRATION FORMULATION FOR ANTI-FXIa ANTIBODIES
AR124866A2 (en) COMPOSITIONS, FORMULATIONS AND PRODUCTION AND PURIFICATION OF INTERLEUKIN
BR112019004210A2 (en) pharmaceutical composition, method and kit for treatment of growth hormone deficiency